Avalo Therapeutics, Inc.
AVTXUnited States
27 filed reports · 330 financial concepts · 0 earnings calls · 0 media appearances
Filed reports
27 reports · Jun 2018 to Jun 2026Each report counts once it has at least one extracted financial fact. Also extracted from these reports: 12 guidance figures.
| Report type | Reports | Facts | Periods |
|---|---|---|---|
| Quarterly · 10-QSEC EDGAR | 15 | 2,107 | Jun 2021 to Jun 2026 |
| Current · 8-KSEC EDGAR | 6 | 12 | Jun 2018 to Sep 2019 |
| Annual · 10-KSEC EDGAR | 5 | 1,860 | Dec 2021 to Dec 2025 |
| Quarterly · 10-Q/ASEC EDGAR | 1 | 121 | Mar 2024 |
Documents
| Period | Type | Period end | Published | Facts | Source |
|---|---|---|---|---|---|
| FY2026 Q2 | 10-Q | Jun 30, 2026 | Aug 6, 2026 | 277 | Open |
| FY2026 Q1 | 10-Q | Mar 31, 2026 | May 13, 2026 | 162 | Open |
| FY2025 | 10-K | Dec 31, 2025 | Mar 23, 2026 | 524 | Open |
| FY2025 Q3 | 10-Q | Sep 30, 2025 | Nov 6, 2025 | 196 | Open |
| FY2025 Q2 | 10-Q | Jun 30, 2025 | Aug 7, 2025 | 133 | Open |
| FY2025 Q1 | 10-Q | Mar 31, 2025 | May 12, 2025 | 116 | Open |
| FY2024 | 10-K | Dec 31, 2024 | Mar 20, 2025 | 323 | Open |
| FY2024 Q3 | 10-Q | Sep 30, 2024 | Nov 7, 2024 | 142 | Open |
| FY2024 Q2 | 10-Q | Jun 30, 2024 | Aug 12, 2024 | 125 | Open |
| FY2024 Q1 | 10-Q/A | Mar 31, 2024 | Jul 11, 2024 | 121 | Open |
| FY2023 | 10-K | Dec 31, 2023 | Mar 29, 2024 | 305 | Open |
| FY2023 Q3 | 10-Q | Sep 30, 2023 | Nov 9, 2023 | 130 | Open |
Financial data
330 concepts · 4,100 factsEach concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.
Financial321 concepts · 3,973 facts · Mar 2020 to Aug 2026
- Research and development42 · Dec 2020 to Jun 2026
- Commercial operations36 · Dec 2020 to Dec 2025
- Stockholders equity (US GAAP)32 · Mar 2020 to Jun 2026
- Allocated share based compensation expense31 · Jun 2020 to Jun 2026
- Cash and cash equivalents at carrying value31 · Jun 2020 to Jun 2026
- Cash cash equivalents restricted cash and restricted cash equivalents31 · Jun 2020 to Jun 2026
- Costs and expenses31 · Jun 2020 to Jun 2026
- Income tax expense benefit31 · Jun 2020 to Jun 2026
- Interest income expense nonoperating net31 · Jun 2020 to Jun 2026
- Net income loss31 · Jun 2020 to Jun 2026
- Nonoperating income expense31 · Jun 2020 to Jun 2026
- Operating income loss31 · Jun 2020 to Jun 2026
- Operating lease cost31 · Jun 2020 to Jun 2026
- Research and development expense excluding acquired in process cost31 · Jun 2020 to Jun 2026
- Restricted cash and cash equivalents at carrying value31 · Jun 2020 to Jun 2026
- Restricted cash and cash equivalents noncurrent31 · Jun 2020 to Jun 2026
- Cash cash equivalents restricted cash and restricted cash equivalents period increase decrease including exchange rate effect30 · Sep 2020 to Jun 2026
- Deferred income tax expense benefit30 · Sep 2020 to Jun 2026
- Depreciation depletion and amortization30 · Sep 2020 to Jun 2026
- Increase decrease in accounts payable30 · Sep 2020 to Jun 2026
- Increase decrease in other accounts payable and accrued liabilities30 · Sep 2020 to Jun 2026
- Increase decrease in prepaid deferred expense and other assets30 · Sep 2020 to Jun 2026
- Lease liability, net30 · Sep 2020 to Jun 2026
- Net cash provided by used in financing activities30 · Sep 2020 to Jun 2026
Segment5 concepts · 65 facts · Dec 2023 to Jun 2026
- Allocated share based compensation expense13 · Dec 2023 to Jun 2026
- Labor and related expense13 · Dec 2023 to Jun 2026
- Other expenses13 · Dec 2023 to Jun 2026
- Reportable Segment13 · Dec 2023 to Jun 2026
- Research and development expense13 · Dec 2023 to Jun 2026
Product3 concepts · 50 facts · Jun 2020 to Dec 2025
- Revenue46 · Jun 2020 to Dec 2025
- Fair value measurement with unobservable inputs reconciliation recurring basis liability issues3 · Dec 2024 to Jun 2025
- Proceeds from license fees received1 · Dec 2022
Guidance1 concepts · 12 facts · Aug 2018 to Nov 2019
- Revenue Guidance12 · Aug 2018 to Nov 2019
Segments
115 factsFigures broken down by business line, region, product or another axis the company reports on.
Statement business segments1 member · 65 facts
- Reportable65 · Dec 2023 to Jun 2026
Product or service4 members · 50 facts
- Product27 · Jun 2020 to Dec 2025
- License18 · Jun 2020 to Mar 2025
- AVTX0074 · Dec 2022 to Jun 2025
- AVTX6111 · Dec 2022
Text from filings
Management commentary and risk factors, extracted from SEC filings only.
No commentary or risk-factor text for this company.
Earnings calls
Transcripts with management claims and analyst questions, one per fiscal period.
No earnings-call transcripts for this company.
Executive media
Podcasts, interviews and conference appearances by the company's executives, with their claims.
No media appearances for this company.
Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Oct 16, 2026) and refreshed every few hours.